(Q50979402)

26 March 2018

title

Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. (English)

1 reference

26 March 2018

1 reference

8

Jedd D Wolchok

1 reference

26 March 2018

author name string

Colin S B Houghton

1

1 reference

26 March 2018

Manuel E Engelhorn

2

1 reference

26 March 2018

Cailan Liu

3

1 reference

26 March 2018

Da Song

4

1 reference

26 March 2018

Polly Gregor

5

1 reference

26 March 2018

Phillip O Livingston

6

1 reference

26 March 2018

Francesca Orlandi

7

1 reference

26 March 2018

James McCracken

9

1 reference

26 March 2018

Alan N Houghton

10

1 reference

26 March 2018

José A Guevara-Patiño

11

1 reference

26 March 2018

language of work or name

English

0 references

publication date

4 June 2007

1 reference

26 March 2018

published in

Vaccine

1 reference

26 March 2018

volume

25

1 reference

26 March 2018

issue

29

1 reference

26 March 2018

page(s)

5330-5342

1 reference

26 March 2018

T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histoc

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Heteroclitic immunization induces tumor immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Optimization of a self antigen for presentation of multiple epitopes in cancer immunity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

SYFPEITHI: database for MHC ligands and peptide motifs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Peptide binding to MHC class I molecules: implications for antigenic peptide prediction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Developing recombinant and synthetic vaccines for the treatment of melanoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Evaluation of CD8(+) T-cell frequencies by the Elispot assay in healthy individuals and in patients with metastatic melanoma immunized with tyrosinase peptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

MHC-binding peptides as immunotherapeutics for cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Specific T cell recognition of peptides derived from prostate-specific antigen in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Structural analysis of MHC class I molecules with bound peptide antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Pocket mutations of HLA-B27 show that anchor residues act cumulatively to stabilize peptide binding.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Endogenous peptides bound to HLA-A3 possess a specific combination of anchor residues that permit identification of potential antigenic peptides.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

A self peptide naturally presented by both H-2Kb and H-2Kbm1 molecules demonstrates MHC restriction of self tolerance at the molecular level

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Crystal structure of an H-2Kb-ovalbumin peptide complex reveals the interplay of primary and secondary anchor positions in the major histocompatibility complex binding groove

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

The melanoma antigen gp75 is the human homologue of the mouse b (brown) locus gene product

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

An endogenous antigenic peptide bypasses the class I antigen presentation defect in RMA-S

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Tumor immunity and autoimmunity induced by immunization with homologous DNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

The use of HLA-A*0201-transfected K562 as standard antigen-presenting cells for CD8(+) T lymphocytes in IFN-gamma ELISPOT assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Human CD8 transgene regulation of HLA recognition by murine T cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Selecting T cell receptors with high affinity for self-MHC by decreasing the contribution of CD8.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Sequence signals for generation of antigenic peptides by the proteasome: implications for proteasomal cleavage mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Combining computer algorithms with experimental approaches permits the rapid and accurate identification of T cell epitopes from defined antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

Assumptions of the tumor 'escape' hypothesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.05.008

10.1016/J.VACCINE.2007.05.008

7 January 2021

Identifiers

DOI

1 reference

26 March 2018

PubMed ID

17570567

1 reference

26 March 2018